Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis
Randomised trials have shown that alteplase improves the odds of a good outcome when delivered within 4·5 h of acute ischaemic stroke. However, alteplase also increases the risk of intracerebral haemorrhage; we aimed to determine the proportional and absolute effects of alteplase on the risks of int...
| Những tác giả chính: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Định dạng: | Journal article |
| Ngôn ngữ: | English |
| Được phát hành: |
Elsevier
2016
|
| _version_ | 1826306968970592256 |
|---|---|
| author | Whiteley, W Emberson, J Lees, K Blackwell, L Albers, G Bluhmki, E Brott, T Cohen, G Davis, S Donnan, G Grotta, J Howard, G Kaste, M Koga, M von Kummer, R Lansberg, M Lindley, R Lyden, P Olivot, J Parsons, M Toni, D Toyoda, K Wahlgren, N Wardlaw, J Del Zoppo, G Sandercock, P Hacke, W Baigent, C |
| author_facet | Whiteley, W Emberson, J Lees, K Blackwell, L Albers, G Bluhmki, E Brott, T Cohen, G Davis, S Donnan, G Grotta, J Howard, G Kaste, M Koga, M von Kummer, R Lansberg, M Lindley, R Lyden, P Olivot, J Parsons, M Toni, D Toyoda, K Wahlgren, N Wardlaw, J Del Zoppo, G Sandercock, P Hacke, W Baigent, C |
| author_sort | Whiteley, W |
| collection | OXFORD |
| description | Randomised trials have shown that alteplase improves the odds of a good outcome when delivered within 4·5 h of acute ischaemic stroke. However, alteplase also increases the risk of intracerebral haemorrhage; we aimed to determine the proportional and absolute effects of alteplase on the risks of intracerebral haemorrhage, mortality, and functional impairment in different types of patients.We used individual patient data from the Stroke Thrombolysis Trialists' (STT) meta-analysis of randomised trials of alteplase versus placebo (or untreated control) in patients with acute ischaemic stroke. We prespecified assessment of three classifications of intracerebral haemorrhage: type 2 parenchymal haemorrhage within 7 days; Safe Implementation of Thrombolysis in Stroke Monitoring Study's (SITS-MOST) haemorrhage within 24-36 h (type 2 parenchymal haemorrhage with a deterioration of at least 4 points on National Institutes of Health Stroke Scale [NIHSS]); and fatal intracerebral haemorrhage within 7 days. We used logistic regression, stratified by trial, to model the log odds of intracerebral haemorrhage on allocation to alteplase, treatment delay, age, and stroke severity. We did exploratory analyses to assess mortality after intracerebral haemorrhage and examine the absolute risks of intracerebral haemorrhage in the context of functional outcome at 90-180 days.Data were available from 6756 participants in the nine trials of intravenous alteplase versus control. Alteplase increased the odds of type 2 parenchymal haemorrhage (occurring in 231 [6·8%] of 3391 patients allocated alteplase vs 44 [1·3%] of 3365 patients allocated control; odds ratio [OR] 5·55 [95% CI 4·01-7·70]; absolute excess 5·5% [4·6-6·4]); of SITS-MOST haemorrhage (124 [3·7%] of 3391 vs 19 [0·6%] of 3365; OR 6·67 [4·11-10·84]; absolute excess 3·1% [2·4-3·8]); and of fatal intracerebral haemorrhage (91 [2·7%] of 3391 vs 13 [0·4%] of 3365; OR 7·14 [3·98-12·79]; absolute excess 2·3% [1·7-2·9]). However defined, the proportional increase in intracerebral haemorrhage was similar irrespective of treatment delay, age, or baseline stroke severity, but the absolute excess risk of intracerebral haemorrhage increased with increasing stroke severity: for SITS-MOST intracerebral haemorrhage the absolute excess risk ranged from 1·5% (0·8-2·6%) for strokes with NIHSS 0-4 to 3·7% (2·1-6·3%) for NIHSS 22 or more (p=0·0101). For patients treated within 4·5 h, the absolute increase in the proportion (6·8% [4·0% to 9·5%]) achieving a modified Rankin Scale of 0 or 1 (excellent outcome) exceeded the absolute increase in risk of fatal intracerebral haemorrhage (2·2% [1·5% to 3·0%]) and the increased risk of any death within 90 days (0·9% [-1·4% to 3·2%]).Among patients given alteplase, the net outcome is predicted both by time to treatment (with faster time increasing the proportion achieving an excellent outcome) and stroke severity (with a more severe stroke increasing the absolute risk of intracerebral haemorrhage). Although, within 4·5 h of stroke, the probability of achieving an excellent outcome with alteplase treatment exceeds the risk of death, early treatment is especially important for patients with severe stroke.UK Medical Research Council, British Heart Foundation, University of Glasgow, University of Edinburgh. |
| first_indexed | 2024-03-07T06:55:58Z |
| format | Journal article |
| id | oxford-uuid:fe283959-73dc-423e-9764-aba582065630 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:55:58Z |
| publishDate | 2016 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:fe283959-73dc-423e-9764-aba5820656302022-03-27T13:34:16ZRisk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:fe283959-73dc-423e-9764-aba582065630EnglishSymplectic Elements at OxfordElsevier2016Whiteley, WEmberson, JLees, KBlackwell, LAlbers, GBluhmki, EBrott, TCohen, GDavis, SDonnan, GGrotta, JHoward, GKaste, MKoga, Mvon Kummer, RLansberg, MLindley, RLyden, POlivot, JParsons, MToni, DToyoda, KWahlgren, NWardlaw, JDel Zoppo, GSandercock, PHacke, WBaigent, CRandomised trials have shown that alteplase improves the odds of a good outcome when delivered within 4·5 h of acute ischaemic stroke. However, alteplase also increases the risk of intracerebral haemorrhage; we aimed to determine the proportional and absolute effects of alteplase on the risks of intracerebral haemorrhage, mortality, and functional impairment in different types of patients.We used individual patient data from the Stroke Thrombolysis Trialists' (STT) meta-analysis of randomised trials of alteplase versus placebo (or untreated control) in patients with acute ischaemic stroke. We prespecified assessment of three classifications of intracerebral haemorrhage: type 2 parenchymal haemorrhage within 7 days; Safe Implementation of Thrombolysis in Stroke Monitoring Study's (SITS-MOST) haemorrhage within 24-36 h (type 2 parenchymal haemorrhage with a deterioration of at least 4 points on National Institutes of Health Stroke Scale [NIHSS]); and fatal intracerebral haemorrhage within 7 days. We used logistic regression, stratified by trial, to model the log odds of intracerebral haemorrhage on allocation to alteplase, treatment delay, age, and stroke severity. We did exploratory analyses to assess mortality after intracerebral haemorrhage and examine the absolute risks of intracerebral haemorrhage in the context of functional outcome at 90-180 days.Data were available from 6756 participants in the nine trials of intravenous alteplase versus control. Alteplase increased the odds of type 2 parenchymal haemorrhage (occurring in 231 [6·8%] of 3391 patients allocated alteplase vs 44 [1·3%] of 3365 patients allocated control; odds ratio [OR] 5·55 [95% CI 4·01-7·70]; absolute excess 5·5% [4·6-6·4]); of SITS-MOST haemorrhage (124 [3·7%] of 3391 vs 19 [0·6%] of 3365; OR 6·67 [4·11-10·84]; absolute excess 3·1% [2·4-3·8]); and of fatal intracerebral haemorrhage (91 [2·7%] of 3391 vs 13 [0·4%] of 3365; OR 7·14 [3·98-12·79]; absolute excess 2·3% [1·7-2·9]). However defined, the proportional increase in intracerebral haemorrhage was similar irrespective of treatment delay, age, or baseline stroke severity, but the absolute excess risk of intracerebral haemorrhage increased with increasing stroke severity: for SITS-MOST intracerebral haemorrhage the absolute excess risk ranged from 1·5% (0·8-2·6%) for strokes with NIHSS 0-4 to 3·7% (2·1-6·3%) for NIHSS 22 or more (p=0·0101). For patients treated within 4·5 h, the absolute increase in the proportion (6·8% [4·0% to 9·5%]) achieving a modified Rankin Scale of 0 or 1 (excellent outcome) exceeded the absolute increase in risk of fatal intracerebral haemorrhage (2·2% [1·5% to 3·0%]) and the increased risk of any death within 90 days (0·9% [-1·4% to 3·2%]).Among patients given alteplase, the net outcome is predicted both by time to treatment (with faster time increasing the proportion achieving an excellent outcome) and stroke severity (with a more severe stroke increasing the absolute risk of intracerebral haemorrhage). Although, within 4·5 h of stroke, the probability of achieving an excellent outcome with alteplase treatment exceeds the risk of death, early treatment is especially important for patients with severe stroke.UK Medical Research Council, British Heart Foundation, University of Glasgow, University of Edinburgh. |
| spellingShingle | Whiteley, W Emberson, J Lees, K Blackwell, L Albers, G Bluhmki, E Brott, T Cohen, G Davis, S Donnan, G Grotta, J Howard, G Kaste, M Koga, M von Kummer, R Lansberg, M Lindley, R Lyden, P Olivot, J Parsons, M Toni, D Toyoda, K Wahlgren, N Wardlaw, J Del Zoppo, G Sandercock, P Hacke, W Baigent, C Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis |
| title | Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis |
| title_full | Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis |
| title_fullStr | Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis |
| title_full_unstemmed | Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis |
| title_short | Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis |
| title_sort | risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke a secondary analysis of an individual patient data meta analysis |
| work_keys_str_mv | AT whiteleyw riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT embersonj riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT leesk riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT blackwelll riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT albersg riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT bluhmkie riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT brottt riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT coheng riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT daviss riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT donnang riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT grottaj riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT howardg riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT kastem riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT kogam riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT vonkummerr riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT lansbergm riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT lindleyr riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT lydenp riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT olivotj riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT parsonsm riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT tonid riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT toyodak riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT wahlgrenn riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT wardlawj riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT delzoppog riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT sandercockp riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT hackew riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis AT baigentc riskofintracerebralhaemorrhagewithalteplaseafteracuteischaemicstrokeasecondaryanalysisofanindividualpatientdatametaanalysis |